Conference
BOLD-100-001 (TRIO039): A phase Ib dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid tumors.
Abstract
TPS145
Background: Although most cancers are initially susceptible to existing anticancer therapies, over time cancer cells develop resistance. BOLD-100 is a first-in-class therapy that targets the GRP78 pathway, a major regulator of cellular stress and resistance. This therapy suppresses drug resistance, survival and proliferation by restraining stress-induced upregulation of GRP78 in tumor cells, leading to inhibition of the …
Authors
O'Kane GM; Spratlin JL; Kavan P; Goodwin RA; McWhirter E; Thompson D; Jones M; McAllister ER; Machado A; Lemmerick Y
Volume
39
Pagination
pp. tps145-tps145
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 20, 2021
DOI
10.1200/jco.2021.39.3_suppl.tps145
Conference proceedings
Journal of Clinical Oncology
Issue
3_suppl
ISSN
0732-183X